Please enable JavaScript to continue using this application.

Compare $TNGX vs $VKTX | Chartloom

Compare

$TNGX vs $VKTX

Tango Therapeutics Inc · Viking Therapeutics Inc

TNGX

Tango Therapeutics Inc

VKTX

Viking Therapeutics Inc

Compare $TNGX vs $VKTX

Comparing Tango Therapeutics Inc and Viking Therapeutics Inc

TNGXTango Therapeutics Inc

VKTXViking Therapeutics Inc

TNGXTango Therapeutics Inc

Market cap

$3.87B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

121.5%

YTD performance

166.6%

52W performance

244.6%

FCF yield

-3.7%

VKTXViking Therapeutics Inc

Market cap

$3.33B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-19.5%

52W performance

-11.9%

FCF yield

-12.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

TNGX

VKTX

Detailed metrics comparison

TNGX

Tango Therapeutics Inc

VKTX

Viking Therapeutics Inc

Market Cap

TNGX$3.87B

VKTX$3.33B

Enterprise Value

TNGX$3.52B

VKTX$3.20B

Price

TNGX$23.81

VKTX$28.51

P/E Ratio

TNGXN/A

VKTXN/A

P/S Ratio

TNGX71.83x

VKTX0.00x

EV/Sales

TNGX65.41x

VKTX0.00x

EV/EBITDA

TNGX0.00x

VKTX0.00x

P/B Ratio

TNGX3.82x

VKTX9.38x

P/FCF Ratio

TNGXN/A

VKTXN/A

EV/FCF

TNGX-24.40x

VKTX-7.65x

PEG Ratio

TNGXN/A

VKTXN/A

Forward P/E (NTM)

TNGXN/A

VKTXN/A

Forward P/S (NTM)

TNGXN/A

VKTXN/A

Revenue (TTM)

TNGX$54M

VKTX$0

Revenue Growth (YoY)

TNGX121.5%

VKTXN/A

Forward Rev Growth

TNGX732.8%

VKTX236.5%

Gross Margin (TTM)

TNGX0.0%

VKTX0.0%

Operating Margin (TTM)

TNGX0.0%

VKTX0.0%

EBITDA Margin (TTM)

TNGX-249.8%

VKTX0.0%

Net Margin (TTM)

TNGX-229.9%

VKTX0.0%

FCF Margin (TTM)

TNGX-268.1%

VKTXN/A

Net Income (TTM)

TNGX$-124M

VKTX$-535M

FCF (TTM)

TNGX$-144M

VKTX$-418M

EPS (TTM)

TNGX-$0.83

VKTX-$4.60

ROE (TTM)

TNGX-2574.0%

VKTX-9456.0%

ROA (TTM)

TNGX-2336.0%

VKTX-8274.0%

ROIC (TTM)

TNGX-2574.0%

VKTX-9456.0%

Cash

TNGX$346M

VKTX$126M

Debt

TNGX$0

VKTX$0

Net Cash/Debt

TNGX$346M

VKTX$126M

Current Ratio (TTM)

TNGX50.82x

VKTX4.72x

Quick Ratio (TTM)

TNGX49.95x

VKTX4.57x

Debt/Equity (TTM)

TNGX0.00x

VKTX0.00x

Debt/Assets (TTM)

TNGX0.0%

VKTX0.0%

Interest Coverage (TTM)

TNGXN/A

VKTXN/A

Net Debt/EBITDA (TTM)

TNGX0.00x

VKTX0.00x

Beta

TNGX1.18

VKTX0.69

52W Performance

TNGX244.6%

VKTX-11.9%

YTD Performance

TNGX166.6%

VKTX-19.5%

% from 52W High

TNGX-30.8%

VKTX-33.9%

% from 52W Low

TNGX255.9%

VKTX10.6%

Asset Turnover (TTM)

TNGX0.26x

VKTX0.00x

FCF Yield (TTM)

TNGX-3.7%

VKTX-12.6%

Earnings Yield (TTM)

TNGX-3.2%

VKTX-16.1%

Dividend Yield (TTM)

TNGXN/A

VKTXN/A

Rule of 40

TNGX-146.6

VKTX0.0

EV/GP/RG

TNGXN/A

VKTXN/A

Ticker research

View TNGX research View VKTX research

Metric	TNGX Tango Therapeutics Inc	VKTX Viking Therapeutics Inc
Market & Valuation
Market Cap	$3.87B	$3.33B
Enterprise Value	$3.52B	$3.20B
Price	$23.81	$28.51
P/E Ratio	N/A	N/A
P/S Ratio	71.83x	0.00x
EV/Sales	65.41x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.82x	9.38x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.40x	-7.65x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$54M	$0
Revenue Growth (YoY)	121.5%	N/A
Forward Rev Growth	732.8%	236.5%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-249.8%	0.0%
Net Margin (TTM)	-229.9%	0.0%
FCF Margin (TTM)	-268.1%	N/A
Net Income (TTM)	$-124M	$-535M
FCF (TTM)	$-144M	$-418M
EPS (TTM)	-$0.83	-$4.60
ROE (TTM)	-2574.0%	-9456.0%
ROA (TTM)	-2336.0%	-8274.0%
ROIC (TTM)	-2574.0%	-9456.0%
Financial Health
Cash	$346M	$126M
Debt	$0	$0
Net Cash/Debt	$346M	$126M
Current Ratio (TTM)	50.82x	4.72x
Quick Ratio (TTM)	49.95x	4.57x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.18	0.69
52W Performance	244.6%	-11.9%
YTD Performance	166.6%	-19.5%
% from 52W High	-30.8%	-33.9%
% from 52W Low	255.9%	10.6%
Efficiency & Yields
Asset Turnover (TTM)	0.26x	0.00x
FCF Yield (TTM)	-3.7%	-12.6%
Earnings Yield (TTM)	-3.2%	-16.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-146.6	0.0
EV/GP/RG	N/A	N/A
Ticker research	View TNGX research	View VKTX research

Valuation

P/S Ratio

VKTX

0.00x

TNGX

71.83x

EV/FCF

TNGX

-24.40x

VKTX

-7.65x

Growth & revenue

Revenue Growth TTM

TNGX

121.5%

Forward Revenue Growth

TNGX

732.8%

VKTX

236.5%

Profitability & performance

Gross Margin

TNGX

0.0%

VKTX

0.0%

ROE

TNGX

-2574.0%

VKTX

-9456.0%

FCF Yield %

TNGX

-3.7%

VKTX

-12.6%

52-Week Performance

TNGX

244.6%

VKTX

-11.9%

Detailed metrics comparison

TNGX

Tango Therapeutics Inc

VKTX

Viking Therapeutics Inc

Market Cap

TNGX$3.87B

VKTX$3.33B

Enterprise Value

TNGX$3.52B

VKTX$3.20B

Price

TNGX$23.81

VKTX$28.51

P/E Ratio

TNGXN/A

VKTXN/A

P/S Ratio

TNGX71.83x

VKTX0.00x

EV/Sales

TNGX65.41x

VKTX0.00x

EV/EBITDA

TNGX0.00x

VKTX0.00x

P/B Ratio

TNGX3.82x

VKTX9.38x

P/FCF Ratio

TNGXN/A

VKTXN/A

EV/FCF

TNGX-24.40x

VKTX-7.65x

PEG Ratio

TNGXN/A

VKTXN/A

Forward P/E (NTM)

TNGXN/A

VKTXN/A

Forward P/S (NTM)

TNGXN/A

VKTXN/A

Revenue (TTM)

TNGX$54M

VKTX$0

Revenue Growth (YoY)

TNGX121.5%

VKTXN/A

Forward Rev Growth

TNGX732.8%

VKTX236.5%

Gross Margin (TTM)

TNGX0.0%

VKTX0.0%

Operating Margin (TTM)

TNGX0.0%

VKTX0.0%

EBITDA Margin (TTM)

TNGX-249.8%

VKTX0.0%

Net Margin (TTM)

TNGX-229.9%

VKTX0.0%

FCF Margin (TTM)

TNGX-268.1%

VKTXN/A

Net Income (TTM)

TNGX$-124M

VKTX$-535M

FCF (TTM)

TNGX$-144M

VKTX$-418M

EPS (TTM)

TNGX-$0.83

VKTX-$4.60

ROE (TTM)

TNGX-2574.0%

VKTX-9456.0%

ROA (TTM)

TNGX-2336.0%

VKTX-8274.0%

ROIC (TTM)

TNGX-2574.0%

VKTX-9456.0%

Cash

TNGX$346M

VKTX$126M

Debt

TNGX$0

VKTX$0

Net Cash/Debt

TNGX$346M

VKTX$126M

Current Ratio (TTM)

TNGX50.82x

VKTX4.72x

Quick Ratio (TTM)

TNGX49.95x

VKTX4.57x

Debt/Equity (TTM)

TNGX0.00x

VKTX0.00x

Debt/Assets (TTM)

TNGX0.0%

VKTX0.0%

Interest Coverage (TTM)

TNGXN/A

VKTXN/A

Net Debt/EBITDA (TTM)

TNGX0.00x

VKTX0.00x

Beta

TNGX1.18

VKTX0.69

52W Performance

TNGX244.6%

VKTX-11.9%

YTD Performance

TNGX166.6%

VKTX-19.5%

% from 52W High

TNGX-30.8%

VKTX-33.9%

% from 52W Low

TNGX255.9%

VKTX10.6%

Asset Turnover (TTM)

TNGX0.26x

VKTX0.00x

FCF Yield (TTM)

TNGX-3.7%

VKTX-12.6%

Earnings Yield (TTM)

TNGX-3.2%

VKTX-16.1%

Dividend Yield (TTM)

TNGXN/A

VKTXN/A

Rule of 40

TNGX-146.6

VKTX0.0

EV/GP/RG

TNGXN/A

VKTXN/A

Ticker research

View TNGX research View VKTX research

Metric	TNGX Tango Therapeutics Inc	VKTX Viking Therapeutics Inc
Market & Valuation
Market Cap	$3.87B	$3.33B
Enterprise Value	$3.52B	$3.20B
Price	$23.81	$28.51
P/E Ratio	N/A	N/A
P/S Ratio	71.83x	0.00x
EV/Sales	65.41x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.82x	9.38x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.40x	-7.65x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$54M	$0
Revenue Growth (YoY)	121.5%	N/A
Forward Rev Growth	732.8%	236.5%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-249.8%	0.0%
Net Margin (TTM)	-229.9%	0.0%
FCF Margin (TTM)	-268.1%	N/A
Net Income (TTM)	$-124M	$-535M
FCF (TTM)	$-144M	$-418M
EPS (TTM)	-$0.83	-$4.60
ROE (TTM)	-2574.0%	-9456.0%
ROA (TTM)	-2336.0%	-8274.0%
ROIC (TTM)	-2574.0%	-9456.0%
Financial Health
Cash	$346M	$126M
Debt	$0	$0
Net Cash/Debt	$346M	$126M
Current Ratio (TTM)	50.82x	4.72x
Quick Ratio (TTM)	49.95x	4.57x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.18	0.69
52W Performance	244.6%	-11.9%
YTD Performance	166.6%	-19.5%
% from 52W High	-30.8%	-33.9%
% from 52W Low	255.9%	10.6%
Efficiency & Yields
Asset Turnover (TTM)	0.26x	0.00x
FCF Yield (TTM)	-3.7%	-12.6%
Earnings Yield (TTM)	-3.2%	-16.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-146.6	0.0
EV/GP/RG	N/A	N/A
Ticker research	View TNGX research	View VKTX research